344 related articles for article (PubMed ID: 22188610)
1. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
2. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery.
Gordon S; Saupe A; McBurney W; Rades T; Hook S
J Pharm Pharmacol; 2008 Dec; 60(12):1591-600. PubMed ID: 19000363
[TBL] [Abstract][Full Text] [Related]
3. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery.
Gordon S; Teichmann E; Young K; Finnie K; Rades T; Hook S
Eur J Pharm Sci; 2010 Oct; 41(2):360-8. PubMed ID: 20633644
[TBL] [Abstract][Full Text] [Related]
5. Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems.
Kojarunchitt T; Baldursdottir S; Dong YD; Boyd BJ; Rades T; Hook S
Eur J Pharm Biopharm; 2015 Jan; 89():74-81. PubMed ID: 25481034
[TBL] [Abstract][Full Text] [Related]
6. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
7. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.
Rizwan SB; McBurney WT; Young K; Hanley T; Boyd BJ; Rades T; Hook S
J Control Release; 2013 Jan; 165(1):16-21. PubMed ID: 23142776
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation.
Myschik J; McBurney WT; Hennessy T; Phipps-Green A; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):224-32. PubMed ID: 18365884
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.
Myschik J; McBurney WT; Rades T; Hook S
Int J Pharm; 2008 Nov; 363(1-2):91-8. PubMed ID: 18692555
[TBL] [Abstract][Full Text] [Related]
10. pH Sensitive phosphorylated chitosan hydrogel as vaccine delivery system for intramuscular immunization.
Wei J; Xue W; Yu X; Qiu X; Liu Z
J Biomater Appl; 2017 May; 31(10):1358-1369. PubMed ID: 28387574
[TBL] [Abstract][Full Text] [Related]
11. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
12. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.
Sexton A; Whitney PG; Chong SF; Zelikin AN; Johnston AP; De Rose R; Brooks AG; Caruso F; Kent SJ
ACS Nano; 2009 Nov; 3(11):3391-400. PubMed ID: 19824668
[TBL] [Abstract][Full Text] [Related]
13. Simple nanoliposomes encapsulating
Bo R; Sun Y; Zhou S; Ou N; Gu P; Liu Z; Hu Y; Liu J; Wang D
Int J Nanomedicine; 2017; 12():6289-6301. PubMed ID: 28894367
[TBL] [Abstract][Full Text] [Related]
14. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
[TBL] [Abstract][Full Text] [Related]
15. Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory.
Wang C; Liu P; Zhuang Y; Li P; Jiang B; Pan H; Liu L; Cai L; Ma Y
Vaccine; 2014 Sep; 32(42):5475-83. PubMed ID: 25110295
[TBL] [Abstract][Full Text] [Related]
16. Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes.
Hjálmsdóttir Á; Bühler C; Vonwil V; Roveri M; Håkerud M; Wäckerle-Men Y; Gander B; Johansen P
Mol Pharm; 2016 Feb; 13(2):320-9. PubMed ID: 26704885
[TBL] [Abstract][Full Text] [Related]
17. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction.
Saint-Lu N; Tourdot S; Razafindratsita A; Mascarell L; Berjont N; Chabre H; Louise A; Van Overtvelt L; Moingeon P
Allergy; 2009 Jul; 64(7):1003-13. PubMed ID: 19220212
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
Myschik J; McBurney WT; Hennessy T; Rades T; Hook S
Pharmazie; 2008 Sep; 63(9):686-92. PubMed ID: 18819523
[TBL] [Abstract][Full Text] [Related]
19. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
[No Abstract] [Full Text] [Related]
20. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
